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Minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC), and minimum biofilm eradication
concentration (MBEC) and kill kinetics were established for vancomycin, rifampicin, trimethoprim, gentamicin, and ciprofloxacin
against the biofilm forming bacteria Staphylococcus epidermidis (ATCC 35984), Staphylococcus aureus (ATCC 29213), Methicillin
Resistant Staphylococcus aureus (MRSA) (ATCC 43300), Pseudomonas aeruginosa (PAO1), and Escherichia coli (NCTC 8196).
MICs and MBCs were determined via broth microdilution in 96-well plates. MBECs were studied using the Calgary Biofilm
Device. Values obtained were used to investigate the kill kinetics of conventional antimicrobials against a range of planktonic
and biofilmmicroorganisms over a period of 24 hours. Planktonic kill kinetics were determined at 4xMIC and biofilm kill kinetics
at relative MBECs. Susceptibility of microorganisms varied depending on antibiotic selected and phenotypic form of bacteria.
Gram-positive planktonic isolates were extremely susceptible to vancomycin (highest MBC: 7.81mg L−1: methicillin sensitive and
resistant S. aureus) but noMBEC value was obtained against all biofilm pathogens tested (up to 1000mg L−1). Both gentamicin and
ciprofloxacin displayed the broadest spectrum of activity with MIC and MBCs in the mg L−1 range against all planktonic isolates
tested and MBEC values obtained against all but S. epidermidis (ATCC 35984) and MRSA (ATCC 43300).
1. Introduction
Medical device related infections present an increasing bur-
den on health care systems with concomitant high rates of
patient morbidity and mortality [1]. Their increased clinical
presentation and associated problems are due mainly to
the ability of microorganisms to form resistant biofilms
at the biomaterial surface. Biofilms are heterogeneous by
nature and contain a subpopulation of dormant persister cells
that show tolerance to treatment by standard antimicrobial
regimens [2]. In the presence of many standard antibiotics
these persister cells reduce metabolic processes and uptake of
nutrients and cease multiplying, only to become active again
when the antibiotic is at subtherapeutic levels [3]. In order to
be clinically successful in the treatment of a medical device
infection, the antibiotic’s pharmacokinetic properties, rate of
kill, and concentration must be assessed against a spectrum
of relevant biofilm forming microorganisms. This study is
set out to obtain an indication of the ability of currently
prescribed antimicrobials to eradicate both planktonic and
biofilm forms of these device related pathogens in vitro, with
conclusions made to their relative success.
On presentation of a medical device related infection
there are several treatment options available. Selection of
treatment is dependent on amultitude of factors including the
location of device and how easily it is available to treatment or
for removal, the likely or proven causative microorganism(s),
the clinical profile/health of the patient and the presence of
comorbidities, and the risk factors for infection. Treatment
strategies can not only vary between different countries and
continents but also differ depending on local antimicrobial
susceptibility data and on antimicrobial formularies/policies
of individual hospitals or health trusts [4].
Updated guidelines published by Mermel et al. provides
accurate guidelines for clinical practice in coordination with
the Infectious Disease Society of America for the diagnosis
and treatment of intravascular catheter-related infections [5].
The two major treatment options involve either removal of
Hindawi Publishing Corporation
Dataset Papers in Science
Volume 2014, Article ID 250694, 10 pages
http://dx.doi.org/10.1155/2014/250694
2 Dataset Papers in Science
the device, for example, a short term peripheral catheter
that is easily removed, or if possible salvaging the device via
use of antimicrobial chemotherapy. Therapy may be initiated
parenterally or through use of the antibiotic lock technique.
The antibiotic lock technique involves filling the catheter
lumen with a high concentration of antimicrobials, com-
monly glycopeptides, ciprofloxacin, and aminoglycosides, for
7–14 days [6]. Such therapy may be used concurrently with
parenteral or oral antimicrobials, anticoagulants, and throm-
bolytics [7–9]. In symptomatic medical device infection, at
risk patients may be initiated on empirical therapy before
the causative pathogen(s) is identified. Empirical therapy can
vary in both length and dosage form but normally consists of
high dose parenteral drugs for 7–10 days with drug of choice
based on suspected pathogen [10, 11]. Where Gram-positive
infections are suspected empirical therapy should involve
an aminoglycoside, for example, gentamicin, or rifampicin
together with the glycopeptide vancomycin [12]. Such a
treatment plan takes into account the potential for methi-
cillin resistant strains to be prevalent. Where methicillin
resistance can be confidently dismissed the penicillinase-
resistant penicillin’s, nafcillin or oxacillin, may be used.
In cases where P. aeruginosa or Gram-negative bacilli are
suspected a cephalosporin (third or fourth generation) may
be utilised including cefepime or ceftazidime and aztreonam
[5]. The potential for antimicrobial resistance to be present
and develop should always be considered upon initiation
of therapy. Organisms should be cultured and susceptibility
tests should be performed to allow treatment to be tapered for
individual infections, thereby allowing a more efficient nar-
row spectrum antimicrobial to be adopted and the potential
for resistance to be lowered.
When coagulase negative staphylococci infection is
implicated vancomycin and other glycopeptides are the
treatment of choice often in combination with teicoplanin
due to the high level of resistance to 𝛽-lactam antibiotics
[13]. Removal of the device may be considered in at risk
patients with 5–7 days of antimicrobial chemotherapy. In
patients where the aim is to salvage the device therapy should
continue for a period of 10–14 days [14, 15]. S. aureus catheter-
related bloodstream infection required the use of intravenous
𝛽-lactam antibiotics, for example, flucloxacillin and oxacillin,
with first generation cephalosporins like cefazolin used on
presentation of penicillin allergic patients if the isolated
microorganism is deemed susceptible [16]. Methicillin resis-
tant S. aureus requires the use of vancomycin alone first
or in combination with rifampicin, fosfomycin, fusidic acid,
cotrimoxazole, clindamycin, or the newer fluoroquinolones if
complications develop [17].
Gram-positive rods including Corynebacterium, Bacil-
lus, and rapidly producing Mycobacterium species are par-
ticularly problematic in medical device related infection.
Their presence normally will require catheter withdrawal
and treatment with intravenous vancomycin [18–20]. For
mycobacteria a range of antibacterials may be required
including aminoglycosides, imipenem/cilastatin, cotrimox-
azole, macrolides, cefoxitin, and tetracyclines [21]. Where
Gram-negative rod infection is implicated catheter with-
drawal may be required if at risk patients are infected with
species other than P. aeruginosa, Acinetobacter baumannii,
Burkholderia cepacia complex, and Stenotrophomonas mal-
tophilia [22]. The most effective antibiotics against E. coli are
imipenem and ciprofloxacin. E. colimay also require the use
of a cephalosporinwith the second generation cephalosporin,
cephamycin, more active than other cephalosporins in treat-
ment of biofilm forming E. coli [23]. P. aeruginosa infec-
tions may involve the use of a third or fourth generation
cephalosporin or carbapenem or an antipseudomonal 𝛽-
lactam like ticarcillin, piperacillin, and mexlocillin in com-
bination with an aminoglycoside [16]. Levofloxacin may also
have a role in treatment schedules [24].
Where circumstances allow intravenous treatment may
be switched to an oral antibiotic. Antibiotics that have been
shown to have high oral bioavailability and tissue penetra-
tion include rifampicin, linezolid, quinolones, for exam-
ple, ciprofloxacin, and a combination of trimethoprim and
sulfamethoxazole (cotrimoxazole) [25]. Choice of antibiotic
treatment is dependent on the nature and severity of infec-
tion. If long term antibiotic intervention fails, as is often the
case, surgery is a requirement for the removal of the device.
As with the majority of medical disease states prevention
of medical device related infection is always considered
preferable to allow infection to become established.
The aim of this study was to compare the in vitro efficacy
of a range of selected antibiotics: vancomycin, rifampicin, tri-
methoprim, gentamicin, and ciprofloxacin, against plank-
tonic and established biofilm forms of medical device related
pathogens (S. epidermidis, S. aureus, MRSA, P. aeruginosa,
and E. coli). Efficacy was measured by obtaining values for
MIC,MBC, andMBEC and determining planktonic and bio-
film kill kinetics.
2. Methodology
Reduced glutathione, vancomycin (as hydrochloride hyd-
rate), rifampicin, trimethoprim, gentamicin (as disulphate
salt), and ciprofloxacin were obtained from Sigma-Aldrich
(Dorset, UK). L-histidine and L-cysteine were obtained
from Novabiochem, Merck Chemicals Ltd. (Nottingham,
UK). Mu¨eller-Hinton broth and Mu¨eller-Hinton agar were
obtained from Oxoid (Basingstoke, UK) and sterilised via
autoclaving, with its sterilised form used throughout the
study. The microorganisms selected for analysis were the
best biofilm forming isolates of each species analysed based
on quantification of biofilm formation results using a crystal
violet staining method employed by Stepanovic´ et al. [26]
and quantifying the growth of different biofilm grown on the
Calgary Biofilm Device. These were S. epidermidis (ATCC
35984), S. aureus (ATCC 29213), MRSA (ATCC 43300), P.
aeruginosa (PAO1), and E. coli (NCTC 8196). All isolates of
microorganisms are stored at −80∘C onMicrobank Preserver
beads (Pro-Lab Diagnostics, Cheshire, UK).
Broth microdilution tests were performed in 96-well
microtitre plates to determine MIC and MBC as described
previously by our group [27]. An original working solution
of each standard antimicrobial was prepared and 0.22𝜇m
sterile was filtered. Antimicrobials tested were vancomycin,
rifampicin, trimethoprim, gentamicin, and ciprofloxacin over
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a double dilution range of 1000–0.24mg L−1. All controls
and test concentrations were prepared as eight replicates.
Biofilm susceptibility assays were performed using the Cal-
gary BiofilmDevice (MBECAssay for Physiology&Genetics,
Innovotech, Edmonton, Alberta, Canada), a rapid, high
throughput assay for the determination of microbial biofilm
susceptibility to antimicrobial challenge. The biofilm assay
was conducted essentially according to the manufacturer’s
instructions, as demonstrated by Ceri et al. [28], with some
slight modifications. The inocula were diluted further in
Mu¨eller-Hinton broth in order to achieve a biofilm viable
count of 2 × 105 CFU/peg after 24 hours.The plates were then
incubated for 24 hours at 37∘C and 95% relative humidity
in a gyrorotary incubator. The original MBEC lid containing
adhere biofilm was placed into the wells of the challenge
plate (containing antimicrobials: 1000–1.95mg L−1) and then
incubated for 24 hours at 37∘C and 95% relative humidity in a
gyrorotary incubator.The recovery plate wells corresponding
to the lowest concentration at which no observable growth
was apparent after 24 hours were also designated to be the
MBEC value. For verification purposes, optical density in
each well was recorded at 550 nm (𝐴
550
) using a Tecan Sun-
rise plate reader and compared with negative (no-growth)
control. Results obtained for MIC, MBC, and MBEC are
displayed in Dataset Item 1 (Table).
For planktonic kill kinetics microorganisms under inves-
tigation were grown over 18–24 hours at 37∘C in Mu¨eller-
Hinton broth and this suspension was further diluted in
static liquid cultures of Quarter Strength Ringers Solution
(QSRS) to approximately 2 × 105 CFUmL−1 stock solution, as
verified by aMiles andMisra total viable count.Antimicrobial
was tested at concentrations of four times the MIC where
MIC was shown to be <1000mg L−1. The selection of an
antimicrobial concentration of four times the MIC allowed
for effective analysis of the kill kinetics of each antimicrobial
as utilised by Stratton et al. [29, 30]. Five replicates of
each antimicrobial/static inoculum solutionwere formulated.
Time points selected to assess planktonic kill kinetics were
10 minutes (0.1667 hours), 1, 1.5, 2, 4, 6, and 24 hours. At
each of these time points the antimicrobial/static inoculum
solution was vortexed and serially diluted using a solution of
universal neutraliser. A stock solution of universal neutraliser
was formed by addition of 1.0 g of L-histidine, 1.0 g of L-
cysteine, and 2.0 g of reduced glutathione to a sterile 20mL
volumetric flask and this was made up accurately to 20mL
using sterile water. To ensure sterility this solutionwas passed
through a syringe with a 0.22𝜇m sterile filter twice. This
stock solution was stored as aliquots in sterile eppendorfs
and frozen at −20∘C until required. 500𝜇L of the universal
neutralizer was added to 20mL of 0.9%NaCl solution for use
in universal inhibitor-rinse plates. Aliquots of each dilution
were added to Mu¨eller-Hinton agar plates and incubated for
24 hours at 37∘C in a stationary incubator and scored for
growth the following day. Drug carryover was also addressed
according to Pankuch et al. [31]. The ability of the standard
antimicrobials to eradicate 24-hour biofilms was evaluated
using MBEC plates similarly to the method used by Smith
et al. [32]. After incubation mature 24-hour biofilm of each
susceptible microorganism was challenged with the MBEC
value of each antimicrobial if the MBEC value was equal
to or lower than 1000mg L−1. No activity corresponds to
MBEC value greater than 1000mg L−1, outside the tested
concentration range, and therefore those antimicrobials were
not tested. A concentration of antimicrobial corresponding
to the MBEC value in QSRS was formulated and added to a
standard 96-well plate with a 200𝜇L volume of antimicrobial
in each well from columns 1 to 5 to form a challenge plate.
Columns 6 to 12 of the challenge plate corresponded to
positive (columns 6–11) and negative controls (column 12)
and contained a 200𝜇L volume of QSRS. The MBEC lid
was placed into the corresponding wells of the challenge
plate and incubated at 37∘C and 95% relative humidity in a
gyrorotary incubator until each corresponding time point is
reached. A dilution plate was set up to include both 0.9%
NaCl solution and universal neutraliser solutions which are
present in separate wells. The first two rows (A and B) of
a standard 96-well plate contained 200 𝜇L of 0.9% NaCl
solution whereas row C contained 200𝜇L of universal neu-
traliser solution. The remaining 5 rows (D–H) corresponded
to serial dilution columns and contained 180𝜇L of 0.9%NaCl
solution in each well. At the time points 0.16667, 1, 1.5, 2, 4,
6, and 24 hours 5 pegs were removed, using sterile flamed
pliers, from the MBEC lid corresponding to antimicrobially
challenged biofilm and further 5 pegs removed from the area
corresponding to positive controls for the biofilm and placed
into the first row of separate wells in corresponding dilution
plates. The first row of wells contained 0.9% NaCl solution
(row A) and corresponded to rinse wells with the removed
pegs being rinsed for 2 minutes before they were moved to
row B for a further 2 minutes rinse via sterile forceps. After
the second rinse the pegs were placed in wells in row C of the
dilution plate that contained universal neutraliser solution
and were sonicated at the highest setting for 10 minutes to
remove adhered microorganism. After sonication the peg
was removed from row C and placed in row B, using sterile
forceps, to ensure that removedmicroorganisms did not read
here. A serial dilution was then performed from rowC to row
H via Miles et al. methods [33] with 20𝜇L aliquots of each
dilution added to Mu¨eller-Hinton agar plates and incubated
for 24 hours at 37∘C in a stationary incubator and scored for
growth the following day. Results for planktonic and biofilm
rate of kill are displayed in Dataset Items 2–18 (Tables) and
represented in Figures 1, 2, 3, 4, 5, 6, 7, 8, and 9.
3. Dataset Description
The dataset associated with this Dataset Paper consists of 18
items which are described as follows.
Dataset Item 1 (Table). MIC, MBC, and MBEC (all mg L−1)
of vancomycin, rifampicin, trimethoprim, gentamicin, and
ciprofloxacin against S. epidermidis (ATCC 35984), S. aureus
(ATCC 29213), MRSA (ATCC 43300), P. aeruginosa (PAO1),
and E. coli (NCTC 8196) based on eight replicates.
Column 1: Antimicrobial
Column 2: MIC against S. epidermidis (mg L−1)
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Figure 1: Log
10
graph showing kill kinetics and Log
10
planktonic
viable counts (Log
10
CFUmL−1) of S. epidermidis (ATCC 35984)
(positive control: open circles, full line) over a period of 24 hours
of exposure to four times MIC value (mg L−1) of active standard
antimicrobials (vancomycin 10mg L−1: filled square, dotted line;
rifampicin 10mg L−1: filled triangle, full line; gentamicin 125mg L−1:
open square, dotted line; ciprofloxacin 4mg L−1: full circle, full line)
based on five replicates.
Column 3: MBC against S. epidermidis (mg L−1)
Column 4: MBEC against S. epidermidis (mg L−1)
Column 5: MIC against S. aureus (mg L−1)
Column 6: MBC against S. aureus (mg L−1)
Column 7: MBEC against S. aureus (mg L−1)
Column 8: MIC against MRSA (mg L−1)
Column 9: MBC against MRSA (mg L−1)
Column 10: MBEC against MRSA (mg L−1)
Column 11: MIC against P. aeruginosa (mg L−1)
Column 12: MBC against P. aeruginosa (mg L−1)
Column 13: MBEC against P. aeruginosa (mg L−1)
Column 14: MIC against E. coli (mg L−1)
Column 15: MBC against E. coli (mg L−1)
Column 16: MBEC against E. coli (mg L−1)
Dataset Item 2 (Table). Rate of kill data (mean) and
logged mean (Log
10
) for planktonic S. epidermidis (ATCC
35984). In the table, the column Antimicrobial presents the
named/relevant antimicrobial and concentration (mg L−1)
where colony count was performed; Time, the exposure
time (hours); Log
10
Planktonic Count, the logged mean
(Log
10
) planktonic count (Log
10
CFUmL−1) of five replicates
at each antimicrobial concentration and time; and Standard
Deviation, the standard deviation of five replicates at each
antimicrobial concentration and time.
Column 1: Antimicrobial
Column 2: Time (h)
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Figure 2: Log
10
graph showing biofilm eradication kinetics and
Log
10
biofilm viable counts (Log
10
CFU/peg) of S. epidermidis
(ATCC 35984) (positive control: open circles, full line) over a
period of 24 hours of exposure to MBEC value (mg L−1) of active
standard antimicrobials (rifampicin 62.5mg L−1: filled triangle, full
line) based on five replicates. Vancomycin, trimethoprim, gentam-
icin, and ciprofloxacin had MBEC values greater than 1000mg L−1
against S. epidermidis (ATCC 35984) and therefore were not tested
for biofilm eradication kinetics.
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Figure 3: Log
10
graph showing kill kinetics and Log
10
planktonic
viable counts (Log
10
CFUmL−1) of S. aureus (ATCC 29213) (positive
control: open circles, full line) over a period of 24 hours of
exposure to four times MIC value (mg L−1) of active standard
antimicrobials (vancomycin 10mg L−1: filled square, dotted line;
rifampicin 1mg L−1: filled triangle, full line; gentamicin 2mg L−1:
open square, dotted line; trimethoprim 10mg L−1: open triangle,
dotted line; ciprofloxacin 10mg L−1: full circle, full line) based on
five replicates.
Column 3: Log
10
Planktonic Count
(Log
10
CFUmL−1)
Column 4: Standard Deviation
Dataset Item 3 (Table). Logged mean (Log
10
) planktonic
count (Log
10
CFUmL−1) of five positive control replicates for
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Figure 4: Log
10
graph showing biofilm eradication kinetics and
Log
10
biofilm viable counts (Log
10
CFU/peg) of S. aureus (ATCC
29213) (positive control: filled diamonds, full line) over a period of
24 hours of exposure to MBEC value (mg L−1) of active standard
antimicrobials (rifampicin 15.63mg L−1: filled triangle, full line; gen-
tamicin 15.63mg L−1: cross, dotted line; ciprofloxacin 500mg L−1:
full circle, full line) based on five replicates. Trimethoprim and
vancomycin had MBEC values greater than 1000mg L−1 against
S. aureus (ATCC 29213) and therefore were not tested for biofilm
eradication kinetics.
planktonic S. epidermidis (ATCC 35984) at each time point
tabulated at the same time as each tested antimicrobial.
Column 1: Time (h)
Column 2: Vancomycin (Log
10
CFUmL−1)
Column 3: Rifampicin (Log
10
CFUmL−1)
Column 4: Gentamicin (Log
10
CFUmL−1)
Column 5: Ciprofloxacin (Log
10
CFUmL−1)
Column 6: Log
10
Planktonic Count
(Log
10
CFUmL−1)
Column 7: Standard Deviation
Dataset Item 4 (Table). Rate of kill data (mean) and logged
mean (Log
10
) for biofilm S. epidermidis (ATCC 35984). Van-
comycin, trimethoprim, gentamicin, and ciprofloxacin had
MBEC values greater than 1000mg L−1 against S. epidermidis
(ATCC 35984) and therefore were not tested for biofilm
eradication kinetics. In the table, the column Antimicrobial
and Positive Control presents the named/relevant antimi-
crobial and concentration (mg L−1) where colony count
was performed followed by the positive control; Time, the
exposure time (hours); Log
10
BiofilmCount, the loggedmean
(Log
10
) biofilm count (Log
10
CFU/peg) of five replicates at
each antimicrobial concentration and time; and Standard
Deviation, the standard deviation of five replicates at each
antimicrobial concentration and time.
Column 1: Antimicrobial and Positive Control
Column 2: Time (h)
Column 3: Log
10
Biofilm Count (Log
10
CFU)
Column 4: Standard Deviation
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Figure 5: Log
10
graph showing kill kinetics and Log
10
planktonic
viable counts (Log
10
CFUmL−1) of MRSA (ATCC 43300) (positive
control: filled circles, full line) over a period of 24 hours of exposure
to four times MIC value (mg L−1) of active standard antimicro-
bials (vancomycin 10mg L−1: filled square, dotted line; rifampicin
10mg L−1: filled triangle, full line; gentamicin 2mg L−1: open square,
dotted line; trimethoprim 250mg L−1: open triangle, dotted line;
ciprofloxacin 31.25mg L−1: full circle, full line) based on five repli-
cates. No standard antimicrobial was active against the biofilm form
of MRSA (ATCC 43300) at concentrations (≤1000mg L−1) tested
and thus kinetic analysis was not performed.
Dataset Item 5 (Table). Rate of kill data (mean) and logged
mean (Log
10
) for planktonic S. aureus (ATCC 29213). In the
table, the column Antimicrobial presents the named/relevant
antimicrobial and concentration (mg L−1) where colony
count was performed; Time, the exposure time (hours);
Log
10
Planktonic Count, the logged mean (Log
10
) planktonic
count (Log
10
CFUmL−1) of five replicates at each antimi-
crobial concentration and time; and Standard Deviation, the
standard deviation of five replicates at each antimicrobial
concentration and time.
Column 1: Antimicrobial
Column 2: Time (h)
Column 3: Log
10
Planktonic Count
(Log
10
CFUmL−1)
Column 4: Standard Deviation
Dataset Item 6 (Table). Logged mean (Log
10
) planktonic
count (Log
10
CFUmL−1) of five positive control replicates
for planktonic S. aureus (ATCC 29213) at each time point
tabulated at the same time as each tested antimicrobial.
Column 1: Time (h)
Column 2: Vancomycin (Log
10
CFUmL−1)
Column 3: Rifampicin (Log
10
CFUmL−1)
Column 4: Gentamicin (Log
10
CFUmL−1)
Column 5: Ciprofloxacin (Log
10
CFUmL−1)
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Figure 6: Log
10
graph showing kill kinetics and Log
10
planktonic
viable counts (Log
10
CFUmL−1) of P. aeruginosa (PAO1) (positive
control: filled circles, full line) over a period of 24 hours of exposure
to four times MIC value (mg L−1) of active standard antimicrobials
(rifampicin 125mg L−1: filled triangle, full line; gentamicin 4mg L−1:
cross, dotted line; ciprofloxacin 1mg L−1: full circle, full line) based
on five replicates.
Column 6: Log
10
Planktonic Count
(Log
10
CFUmL−1)
Column 7: Standard Deviation
Dataset Item 7 (Table). Rate of kill data (mean) and logged
mean (Log
10
) for biofilm S. aureus (ATCC 29213). Trimetho-
prim and vancomycin had MBEC values greater than
1000mg L−1 against S. aureus (ATCC 29213) and therefore
were not tested for biofilm eradication kinetics. In the
table, the column Antimicrobial presents the named/relevant
antimicrobial and concentration (mg L−1) where colony
count was performed; Time, the exposure time (hours);
Log
10
Biofilm Count, the logged mean (Log
10
) biofilm count
(Log
10
CFU/peg) of five replicates at each antimicrobial con-
centration and time; and Standard Deviation, the standard
deviation of five replicates at each antimicrobial concentra-
tion and time.
Column 1: Antimicrobial
Column 2: Time (h)
Column 3: Log
10
Biofilm Count (Log
10
CFU)
Column 4: Standard Deviation
Dataset Item 8 (Table). Logged mean (Log
10
) biofilm count
(Log
10
CFU/peg) of five positive control replicates for biofilm
S. aureus (ATCC 29213) at each time point tabulated at the
same time as each tested antimicrobial.
Column 1: Time (h)
Column 2: Vancomycin (Log
10
CFU)
Column 3: Rifampicin (Log
10
CFU)
Column 4: Gentamicin (Log
10
CFU)
Column 5: Ciprofloxacin (Log
10
CFU)
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Figure 7: Log
10
graph showing biofilm eradication kinetics and
Log
10
biofilmviable counts (Log
10
CFU/peg) ofP. aeruginosa (PAO1)
(positive control: open circle, full line) over a period of 24 hours of
exposure to MBEC value (mg L−1) of active standard antimicrobials
(gentamicin 125mg L−1: open square, dotted line; ciprofloxacin
3.91mg L−1: full circle, full line) based on five replicates. Van-
comycin, trimethoprim, and rifampicin had MBEC values greater
than 1000mg L−1 against P. aeruginosa (PAO1) and therefore were
not tested for biofilm eradication kinetics.
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Figure 8: Log
10
graph showing kill kinetics and Log
10
planktonic
viable counts (Log
10
CFUmL−1) of E. coli (NCTC 8196) (positive
control: open circle, full line) over a period of 24 hours of exposure
to four times MIC value (mg L−1) of active standard antimicrobials
(vancomycin 1000mg L−1: filled square, dotted line; rifampicin
62.5mg L−1: filled triangle, full line; gentamicin 10mg L−1: open
square, dotted line; trimethoprim 1mg L−1: open triangle, dotted
line; ciprofloxacin 1mg L−1: full circle, full line) based on five
replicates.
Column 6: Log
10
Biofilm Count (Log
10
CFU)
Column 7: Standard Deviation
Dataset Item 9 (Table). Rate of kill data (mean) and logged
mean (Log
10
) for planktonic MRSA (ATCC 43300). In the
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Figure 9: Log
10
graph showing biofilm eradication kinetics and
Log
10
biofilm viable counts (Log
10
CFU/peg) of E. coli (NCTC 8196)
(positive control: open circles, full line) over a period of 24 hours of
exposure to MBEC value (mg L−1) of active standard antimicrobials
(gentamicin 15.63mg L−1: open square, dotted line; trimethoprim
62.5mg L−1: open triangle, dotted line; ciprofloxacin 7.81mg L−1: full
circle, full line) based on five replicates. Vancomycin and rifampicin
hadMBEC values greater than 1000mg L−1 against of E. coli (NCTC
8196) and therefore were not tested for biofilm eradication kinetics.
table, the column Antimicrobial presents the named/relevant
antimicrobial and concentration (mg L−1) where colony
count was performed; Time, the exposure time (hours);
Log
10
Planktonic Count, the logged mean (Log
10
) planktonic
count (Log
10
CFUmL−1) of five replicates at each antimi-
crobial concentration and time; and Standard Deviation, the
standard deviation of five replicates at each antimicrobial
concentration and time.
Column 1: Antimicrobial
Column 2: Time (h)
Column 3: Log
10
Planktonic Count
(Log
10
CFUmL−1)
Column 4: Standard Deviation
Dataset Item 10 (Table). Logged mean (Log
10
) planktonic
count (Log
10
CFUmL−1) of five positive control replicates for
planktonicMRSA (ATCC43300) at each time point tabulated
at the same time as each tested antimicrobial.
Column 1: Time (h)
Column 2: Vancomycin (Log
10
CFUmL−1)
Column 3: Rifampicin (Log
10
CFUmL−1)
Column 4: Gentamicin (Log
10
CFUmL−1)
Column 5: Trimethoprim (Log
10
CFUmL−1)
Column 6: Ciprofloxacin (Log
10
CFUmL−1)
Column 7: Log
10
Planktonic Count
(Log
10
CFUmL−1)
Column 8: Standard Deviation
Dataset Item 11 (Table). Rate of kill data (mean) and logged
mean (Log
10
) for planktonic P. aeruginosa (PAO1). In the
table, the column Antimicrobial presents the named/relevant
antimicrobial and concentration (mg L−1) where colony
count was performed; Time, the exposure time (hours);
Log
10
Planktonic Count, the logged mean (Log
10
) planktonic
count (Log
10
CFUmL−1) of five replicates at each antimi-
crobial concentration and time; and Standard Deviation, the
standard deviation of five replicates at each antimicrobial
concentration and time.
Column 1: Antimicrobial
Column 2: Time (h)
Column 3: Log
10
Planktonic Count
(Log
10
CFUmL−1)
Column 4: Standard Deviation
Dataset Item 12 (Table). Logged mean (Log
10
) planktonic
count (Log
10
CFUmL−1) of five positive control replicates for
planktonic P. aeruginosa (PAO1) at each time point tabulated
at the same time as each tested antimicrobial.
Column 1: Time (h)
Column 2: Rifampicin (Log
10
CFUmL−1)
Column 3: Gentamicin (Log
10
CFUmL−1)
Column 4: Ciprofloxacin (Log
10
CFUmL−1)
Column 5: Log
10
Planktonic Count
(Log
10
CFUmL−1)
Column 6: Standard Deviation
Dataset Item 13 (Table). Rate of kill data (mean) and logged
mean (Log
10
) for biofilm P. aeruginosa (PAO1). Vancomycin,
trimethoprim, and rifampicin hadMBEC values greater than
1000mg L−1 against P. aeruginosa (PAO1) and therefore were
not tested for biofilm eradication kinetics. In the table, the
column Antimicrobial presents the named/relevant antimi-
crobial and concentration (mg L−1) where colony count
was performed; Time, the exposure time (hours); Log
10
BiofilmCount, the loggedmean (Log
10
) biofilm count (Log
10
CFU/peg) of five replicates at each antimicrobial concentra-
tion and time; and Standard Deviation, the standard devia-
tion of five replicates at each antimicrobial concentration and
time.
Column 1: Antimicrobial
Column 2: Time (h)
Column 3: Log
10
Biofilm Count (Log
10
CFU)
Column 4: Standard Deviation
Dataset Item 14 (Table). Logged mean (Log
10
) biofilm count
(Log
10
CFU/peg) of five positive control replicates for biofilm
P. aeruginosa (PAO1) at each time point tabulated at the same
time as each tested antimicrobial.
Column 1: Time (h)
Column 2: Gentamicin (Log
10
CFU)
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Column 3: Ciprofloxacin (Log
10
CFU)
Column 4: Log
10
Biofilm Count (Log
10
CFU)
Column 5: Standard Deviation
Dataset Item 15 (Table). Rate of kill data (mean) and logged
mean (Log
10
) for planktonic E. coli (NCTC 8196). In the
table, the column Antimicrobial presents the named/relevant
antimicrobial and concentration (mg L−1) where colony
count was performed; Time, the exposure time (hours);
Log
10
Planktonic Count, the logged mean (Log
10
) planktonic
count (Log
10
CFUmL−1) of five replicates at each antimi-
crobial concentration and time; and Standard Deviation, the
standard deviation of five replicates at each antimicrobial
concentration and time.
Column 1: Antimicrobial
Column 2: Time (h)
Column 3: Log
10
Planktonic Count
(Log
10
CFUmL−1)
Column 4: Standard Deviation
Dataset Item 16 (Table). Logged mean (Log
10
) planktonic
count (Log
10
CFUmL−1) of five positive control replicates for
planktonic E. coli (NCTC 8196) at each time point tabulated
at the same time as each tested antimicrobial.
Column 1: Time (h)
Column 2: Vancomycin (Log
10
CFUmL−1)
Column 3: Rifampicin (Log
10
CFUmL−1)
Column 4: Gentamicin (Log
10
CFUmL−1)
Column 5: Trimethoprim (Log
10
CFUmL−1)
Column 6: Ciprofloxacin (Log
10
CFUmL−1)
Column 7: Log
10
Planktonic Count
(Log
10
CFUmL−1)
Column 8: Standard Deviation
Dataset Item 17 (Table). Rate of kill data (mean) and logged
mean (Log
10
) for biofilm E. coli (NCTC 8196). Vancomycin
and rifampicin had MBEC values greater than 1000mg L−1
against of E. coli (NCTC 8196) and therefore were not tested
for biofilm eradication kinetics. In the table, the column
Antimicrobial presents the named/relevant antimicrobial and
concentration (mg L−1) where colony count was performed;
Time, the exposure time (hours); Log
10
Biofilm Count, the
logged mean (Log
10
) biofilm count (Log
10
CFU/peg) of five
replicates at each antimicrobial concentration and time; and
Standard Deviation, the standard deviation of five replicates
at each antimicrobial concentration and time.
Column 1: Antimicrobial
Column 2: Time (h)
Column 3: Log
10
Biofilm Count (Log
10
CFU)
Column 4: Standard Deviation
Dataset Item 18 (Table). Logged mean (Log
10
) biofilm count
(Log
10
CFU/peg) of five positive control replicates for biofilm
E. coli (NCTC 8196) at each time point tabulated at the same
time as each tested antimicrobial.
Column 1: Time (h)
Column 2: Gentamicin (Log
10
CFU)
Column 3: Trimethoprim (Log
10
CFU)
Column 4: Ciprofloxacin (Log
10
CFU)
Column 5: Log
10
Biofilm Count (Log
10
CFU)
Column 6: Standard Deviation
4. Concluding Remarks
The use of standard antimicrobials in biomaterial-associated
infection is to either salvage the medical device or prevent
infection by incorporation of the antimicrobial into the
device [25, 34]. As the results obtained have shown there
are differences in both the spectrum of activity of the
antimicrobials and also in their relative activity against
planktonic and biofilm forms of these numerous device
related pathogens. The formation of biofilms by microorgan-
isms leads to an almost universal ten- to one-thousand-fold
increase in the concentration of antimicrobial required to
eradicate established infection [35]. This paper is significant
in providing in vitro data on standardly used antibiotic
regimens to inform the initial clinical treatment choice for
medical device related infections. None of the antimicrobials
tested were fully microbicidal against all forms of Gram-
positive and Gram-negative microorganisms researched at
the concentrations tested. Thus, as is the case clinically, it is
often required to use combinations of antimicrobials both
to provide better antimicrobial coverage in the treatment
of infection and to reduce the incidence of resistance
developing to a particular antimicrobial [36]. Rifampicin
had the best activity against Gram-positive microorganisms
with gentamicin possessing the greatest spectrum of activity
overall. The Gram-negative microorganisms were most
susceptible to ciprofloxacin. Despite its mainly intracellular
action rifampicin showed excellent kill kinetics of both
planktonic (1mg L−1) and biofilm (15.63mg L−1) forms of S.
aureus (ATCC 29213) within 1.5 and 6 hours, respectively.
However in the majority of cases where an MBEC value
was obtained, a 24-hour challenge with the antimicrobial
was required to completely eradicate the biofilm. This delay
in kill is crucial in promoting the formation of resistant
microorganisms, particularly of the sessile biofilm form
and persister cells. The incidence of resistance to standard
antimicrobial regimens and the need for novel antimicrobial
compounds with multiple modes of action are increasing
[37]. Therefore obtaining the MIC, MBC, and MBEC
values and establishing the kill kinetics of these standard
antimicrobials against experimental biofilm forming isolates
allow comparisons to be made with values obtained for novel
compounds, such as antimicrobial peptides [38], with their
relative effectiveness judged accordingly. There is also the
potential that these novel compounds may act synergistically
with standard antimicrobials to lower both the development
Dataset Papers in Science 9
of microbial resistance and the therapeutic doses required to
resolve or prevent infection.
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